Omeros Financial Statements
NASDAQ: OMERHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.83+0.71 (+3.71%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Omeros revenue and earnings
Omeros reported a net loss of $3.4 million, compared with a loss of $156.8 million a year earlier. Diluted earnings per share came in at -$0.05.
Summary generated from market data by MetaCap's automated system. Methodology
Omeros income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | 73.81M | 111.81M | 29.87M | 64.83M | 41.62M |
| Revenue growth (YoY) | — | — | — | — | — | -33.98% | +274.33% | -53.93% | +55.77% | +208.07% |
| Cost of Revenue | — | — | — | — | — | 902.00K | 865.00K | 512.00K | 1.08M | 1.41M |
| Gross Profit | — | — | — | — | — | 72.91M | 110.94M | 29.36M | 63.75M | 40.20M |
| Operating Expenses | — | — | — | — | — | 229.83M | 256.98M | 142.09M | 108.72M | 95.89M |
| Research & Development | 81.30M | 119.52M | 114.87M | 112.72M | 118.78M | 107.61M | 106.32M | 89.86M | 55.60M | 50.70M |
| Selling, General & Admin | 41.50M | 47.43M | 49.66M | 50.67M | 54.84M | — | — | — | — | — |
| Operating Income | -122.80M | -166.95M | -164.53M | -163.39M | -173.62M | -156.92M | -146.04M | -112.22M | -43.90M | -54.28M |
| Interest Expense | -960.00K | 24.68M | 30.84M | 22.70M | 19.67M | 26.75M | 22.66M | 16.25M | 11.03M | 7.82M |
| Other Income (Expense) | — | — | — | — | 1.74M | 654.00K | 1.55M | 1.78M | 1.44M | 945.00K |
| Pretax Income | -2.80M | -180.32M | -174.92M | -182.03M | -191.55M | -196.39M | -167.14M | -139.69M | -53.48M | -66.75M |
| Income Tax | 2.01M | 2.31M | 0 | 0 | 0 | -23.26M | -19.77M | -12.93M | 0 | 0 |
| Net Income | -3.35M | -156.81M | -117.81M | 47.42M | 194.24M | -138.06M | -84.49M | -126.76M | -53.48M | -66.75M |
| Net Income growth (YoY) | — | — | -348.46% | -75.59% | — | — | — | — | — | — |
| EPS (Basic) | -0.05 | -2.70 | -1.88 | 0.76 | 3.12 | -2.41 | -1.71 | -2.61 | -1.17 | -1.65 |
| EPS (Diluted) | -0.05 | -2.70 | -1.88 | 0.76 | 3.12 | -2.41 | -1.71 | -2.61 | -1.17 | -1.65 |
| Shares Outstanding (Basic) | 63.51M | 58.17M | 62.74M | 62.74M | 62.34M | 57.18M | 49.52M | 48.58M | 45.54M | 40.45M |
| Shares Outstanding (Diluted) | — | — | — | 62.74M | 62.34M | 57.18M | 49.52M | 48.58M | 45.54M | 40.45M |
| EBITDA | -121.83M | -166.00M | -163.61M | -162.44M | -172.23M | -155.30M | -144.25M | -111.26M | -43.34M | -53.98M |
| Gross Margin | — | — | — | — | — | 98.78% | 99.23% | 98.29% | 98.34% | 96.61% |
| Operating Margin | — | — | — | — | — | -212.59% | -130.62% | -375.73% | -67.71% | -130.42% |
| Net Margin | — | — | — | — | — | -187.04% | -75.57% | -424.39% | -82.50% | -160.38% |
This table shows 10 annual periods of Omeros's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow OMER's reporting calendar. What is a income statement?